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Abstract  
Ethnopharmacological relevance: Yahom is a traditional Thai medicine used to treat syncope 
and abdominal discomfort.    
Aim of the study: This study aimed to systematically review all available evidence which 
purports to support these claims.  
Material and methods: The systematic review accorded with the Cochrane Collaboration 
framework and PRISMA reporting.  Databases including MEDLINE, Excerpta Medica 
Database (EMBASE), Cochrane library database, and Google Scholar were searched by 
keywords, Yahom and Ya-hom. Pharmacological and toxicity data from non-animal and 
animal studies were included.  
Results: Twenty-four articles: 2 on in vitro cell lines or bacteria, 3 in vitro cell-free, 5 in vitro 
animal, 13 in vivo and 1 human mainly reported (A) Cardiovascular effects (i) transient 
hypotension (0.2-0.8 g/kg, intravenous injection (i.v.)), increased cerebral blood flow (2 g/kg, 
single oral) and vascular dilatation/relaxation (ii) elevated blood pressure (BP) (0.2-0.8 g/kg, 
i.v. or 2-4 g/kg oral) and vasocontraction.  Single Yahom doses (3 g) given to healthy 
volunteers had no effect on cutaneous blood flow, ECG or systolic BP although marginally 
increased diastolic BP was claimed. (B) Yahom (2-4 g/kg) completely inhibited gastric acid 
secretion evoked by gastric secretagogues. (C) Toxicity: Chronic oral doses of selected 
Yahoms to rodents (0.001-1 g/kg) supports its status as generally regarded as safe.  
Conclusions: Most studies supported declared objectives relating to perceived Yahom 
actions, but lacked background demonstrating clinical efficacy, and mechanistic data that 
would validate conclusions.  Our study suggests that research into traditional medicinal 
herbs needs underpinning by appropriate clinical interventions and pharmacovigilance, 
thereby optimising efficacy and minimizing toxicity by combining traditional wisdom and 
modern testing.  
Key words: Thai traditional herbs, Yahom, Ya-hom, systematic review, folk medicines, herbal 
medicines  
Running title: Yahom and its pharmacology  
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1. Introduction  
Many folk and traditional medicines are founded on complex mixtures of natural 
ingredients and continue to be used widely throughout the world (World Health Organization, 
2013).  One of these is Yahom (meaning nice-smelling drug in Thai) which has a long history 
as a remedy for fainting, dizziness, flatulence, and abdominal discomfort (Department for 
development of Thai traditional and alternative medicine: Ministry of Public Health, 2011; 
Ministry of Public Health, 1999).  Yahom is a generic term for preparations sold under 
numerous brand names all having different compositions and formulations and ~100 of these 
Yahom preparations are registered as traditional medicines with the Thai Food and Drug 
Administration that oversees their manufacture and sale.  Only five (Tip Osot, Tepajit, 
Navagot, Kae Lom Wing Wien, and Intarachak or Intajak) are registered on the Thai National 
List of Herbal Medicinal Products which considers ethnopharmacological evidence and 
efficacy.  Each Yahom is formulated from 30-60 components of desiccated medicinal plant 
parts ground into powders or tablets (Department for development of Thai traditional and 
alternative medicine: Ministry of Public Health, 2011).  Ingredients and amounts are variable 
but the following plants are common to Yahom preparations e.g Pierre ex Lecomte, Mesua 
ferrea  L., Mimusops elengi L., Cinnamomum loureirii Nees., Saussurea lappa C.B. Clarke, 
Angelica dahurica, Ligusticum chuanxiong Hort  (Department for development of Thai 
traditional and alternative medicine: Ministry of Public Health, 2011).  They are administered 
as tablets, or suspensions after soaking in hot water.  Product labelling usually contains 
some information about product origin, recommended dosages and frequency, and 
symptoms appropriate to the medication.  For others, recommendations are scant. 
Yahom continues to enjoy widespread use, mainly among older Thais.  It is usually 
used for acute conditions.  Thus, a better understanding of their efficacy, interactions and 
adverse actions is needed to promote and protect public health and safety.  Thus far, most 
scientific data about Yahom is derived from animal and in vitro studies (Jariyapongskul et al., 
2006; Suvitayavat et al., 2004; Suvitayavat et al., 2005a).  To date, no systematic review 
which integrates and assesses the reliability of this evidence on Yahom has been 
undertaken.  Although systematic reviews normally correlate clinical studies (Higgins and 
Green, 2011), this approach is also a valuable strategy to correlate preclinical data thus 
helping to rationally direct future clinical work (Andersen et al., 2014; Liao et al., 2014; 
Ranasinghe et al., 2012).  Therefore, the current study aims to systematically evaluate the 
evidence for Yahom efficacy and safety using in vitro, in vivo preclinical and clinical studies.  
In this, we identify several fundamental deficiencies in the studies and because of its 
widespread use, these need to be addressed.  
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2. Materials and methods  
This systematic review was conducted according to the Cochrane Collaboration 
framework and reporting followed the PRISMA Statement (Higgins and Green, 2011; Moher 
et al., 2009). 
2.1 Literature search  
The following bibliographic databases were systematically searched since their 
inception dates to March 2016: MEDLINE, Excerpta Medica Database (EMBASE), Cochrane 
library database, and Google Scholar.  The search terms: Yahom and Ya-hom were used.  A 
manual search was performed using the references and asking experts on Yahom to seek 
additional data. Government reports and dissertation were also used as sources of data.  
Authors of the reports and papers were contacted where necessary to clarify missing or 
incomplete data, although some were unable or unwilling to provide extra data.  We 
identified all relevant studies regardless of language.  
2.2 Inclusion criteria  
The inclusion criteria were studies that investigated the pharmacological effects and 
toxicities of Yahom in non-animal, animal, or human experiments.  Review articles, 
abstracts, letters to the editor, comments, case reports and duplicated study populations 
were excluded.  
2.3 Data extraction and analysis  
Two reviewers (KC, CNS) independently reviewed and extracted the data using a 
common data extraction procedure.  Data extraction for preclinical studies included animal & 
study models, Yahom brand and preparation, concentration/dose, route of administration 
and duration of treatment, protocols and outcome parameters measured and techniques 
used, and basic pharmacological data.  The details of the extracted preclinical data of 
Yahom are summarised in Tables 1-3.  A human study was extracted by study design, 
subject characteristics, Yahom preparation, intervention, outcome parameters, and results.  
2.4 Quality assessment  
Quality assessment was performed in animal and human studies.  Animal studies 
were assessed for quality based on an approach proposed by Krauth et al. (Krauth et al., 
2013), which included domains about sequence generation, allocation concealment, 
observer blinding to allocation (personnel collecting or analysing data were unaware of which 
subjects belonged to intervention or control groups), inclusion and exclusion criteria, sample 
size, animal welfare regulations, a conflict of interest statement, statistical tests, animal 
selection based on comorbidity, baseline data for the animals, dose-response model, 
withdrawal of animals from the study, time to the outcome assessment, and adequate 
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controls.  We also added enough protocol and method information to repeat the study, and 
also 4 domains on herbal medicines which are supplementary to ARRIVE and CONSORT 
statements (Kilkenny et al., 2012; Gagnier et al., 2006).  Use of positive controls and 
taxonomic validation of medicinal plant composition was also assessed.  Risk of bias 
assessment and the CONSORT statement were used for the human study (Higgins and 
Green, 2011; Moher et al., 2010).  
  
3. Results  
3.1 Search results  
A total of 35 articles were identified from the database searches.  Nine additional 
articles were identified through manual searches of the references, bibliographies and 
consultations with experts.  This yielded 24 articles which met the inclusion criteria including 
2 in vitro cell lines or bacteria (Sripanidkulchai et al., 2007; Tepsuwan et al., 2011), 3 in vitro 
cell-free (Channarong et al., 2012; Nalinratana et al., 2014; Tuekaew et al., 2014), 5 in vitro 
animal tissue studies (Chantharangsikul et al., 2009; Nonthasawadsri et al., 2015; 
Nusuetrong et al., 2012; Pataloong and Sawasdimongkol, 1995; Suvitayavat et al., 2005b), 
13 in vivo animal studies (Chavalittumrong et al., 2009; Intayoong, 2006; Jariyapongskul et 
al., 2006; Kengkoom and Ampawong, 2015; Kengkoom et al., 2012; Kengkoom et al., 2015; 
Matangkasombat, 1974; Nernpermpisooth et al., 2015; Sirisangtragul and Sripanidkulchai, 
2013; Sirisangtrakul and Sripanidkulchai, 2011; Suvitayavat et al., 2004; Suvitayavat et al., 
2005a; Thongpraditchote et al., 1999) and 1 human study (Suvitayavat  et al., 2005) (Fig 1).   
3.2 Study characteristics 
 The in vivo or in vitro experimental studies using either normal rats or mice (n = 3-16 per 
group for in vivo and n = 5-10 per group for in vitro studies), were performed to determine 
pharmacological actions of Yahom.  In all studies, animals were allocated equally to each 
arm (control groups, receiving vehicle only and one or several different Yahom doses 
dissolved in vehicle).  The cardiovascular system was the main focus in preclinical studies 
(Table 1).  Mean arterial blood pressure (MAP) was measured in two in vivo studies on 
normal anesthetized rats after either intravenous or oral administration of Yahom 
(Jariyapongskul et al., 2006; Suvitayavat et al., 2004), and two in vitro studies measured 
contraction of rat isolated aorta or atria (Nusuetrong et al., 2012; Suvitayavat et al., 2005b).  
One study included cerebral blood flow (Jariyapongskul et al., 2006).  Actions on the 
gastrointestinal system, another target possibly relevant to Yahom ethnopharmacology, were 
assessed as: (i) gastric acid secretion evoked by histamine or muscarinic agonists using 
either normal anesthetized rat (Suvitayavat et al., 2004) or isolated mouse whole stomach 
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(Chantharangsikul et al., 2009); or (ii) protection against ulceration in rats (Intayoong, 2006) 
(Table 2).  Acute (14 days) and chronic (6 months) toxicity was tested in rats and mice 
(Chavalittumrong et al., 2009) and P450 enzyme function was measured in orally dosed 
mice for 4 weeks (Sirisangtragul and Sripanidkulchai, 2013; Sirisangtrakul and 
Sripanidkulchai, 2011). 
The human study recruited 15 healthy females (age 20-23 yr) into an acute cross-
over trial. Five Pagodas brand was administered as a single oral dose as an aqueous 
suspension (3 g) or a lyophilized aqueous extract (Suvitayavat et al., 2005) (Table 4).  
Electrocardiogram (ECG), blood pressure and forearm cutaneous blood flow were measured 
every 5 min for 60 min. 
3.3 Nature of Yahom tested  
All studies used different formulae and preparations of Yahom.  Between the eight 
animal studies (Chavalittumrong et al., 2009; Kengkoom and Ampawong, 2015; Kengkoom 
et al., 2012; Kengkoom et al., 2015; Sirisangtragul and Sripanidkulchai, 2013; Sirisangtrakul 
and Sripanidkulchai, 2011; Suvitayavat et al., 2004; Suvitayavat et al., 2005a), four Yahom 
formulas were tested in all (Five Pagodas, Intajak, Navagot, Ampanthong, and Tultavai).   
Another study evaluated Prasarthong (Sripanidkulchai et al., 2007) while in 9 studies 
(Channarong et al., 2012; Intayoong, 2006; Jariyapongskul et al., 2006; Matangkasombat, 
1974; Nernpermpisooth et al., 2015; Pataloong and Sawasdimongkol, 1995; Suvitayavat et 
al., 2005b; Tepsuwan et al., 2011; Thongpraditchote et al., 1999), the source and formulation 
were unreported, although 2 studies (Intayoong, 2006; Sirisangtrakul and Sripanidkulchai, 
2011) listed the qualitative ingredients.   
All studies used extracts rather than the raw commercial preparations that are 
consumed by users, except in one arm of the clinical study (Suvitayavat et al., 2005).  The 
extracts were 5-19% of the original product by dry weights and the solvent was either water 
(Chantharangsikul et al., 2009; Intayoong, 2006; Suvitayavat et al., 2004; Suvitayavat  et al., 
2005; Suvitayavat et al., 2005a; Suvitayavat et al., 2005b), EtOH (Nusuetrong et al., 2012), 
or 80% EtOH, and 2 studies used MeCl2, MeOH or water (Sirisangtragul and 
Sripanidkulchai, 2013; Sirisangtrakul and Sripanidkulchai, 2011). The extraction 
temperature, solvent volume, period, and mechanical treatment also varied.    
Many studies quoted doses as a raw powder equivalent (Chantharangsikul et al., 
2009; Nernpermpisooth et al., 2015; Pataloong and Sawasdimongkol, 1995; Sirisangtragul 
and Sripanidkulchai, 2013; Sirisangtrakul and Sripanidkulchai, 2011; Suvitayavat  et al., 
2005; Suvitayavat et al., 2005a; Suvitayavat et al., 2005b), otherwise all studies quoted the 
actual doses/concentrations of extract.  The human study used the native powder, in one 
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study arm (Suvitayavat et al., 2005).  The rationales for using extracts or doses were not 
stated. 
3.4 Quality assessment 
Thirteen in vivo animal studies (Chavalittumrong et al., 2009; Intayoong, 2006; 
Jariyapongskul et al., 2006; Kengkoom and Ampawong, 2015; Kengkoom et al., 2012; 
Kengkoom et al., 2015; Matangkasombat, 1974; Nernpermpisooth et al., 2015; 
Sirisangtragul and Sripanidkulchai, 2013; Sirisangtrakul and Sripanidkulchai, 2011; 
Suvitayavat et al., 2004; Suvitayavat et al., 2005a; Thongpraditchote et al., 1999) were 
assessed for their quality (Table 5).  In all studies, sample size was clearly given and 
investigation time was sufficient for outcome assessment, but the allocation sequence, 
concealment, and blinding were unclear.  None of the studies stated inclusion and exclusion 
criteria and only two of them detailed when animals were removed from study (Sirisangtragul 
and Sripanidkulchai, 2013; Sirisangtrakul and Sripanidkulchai, 2011).  Complying with animal 
welfare regulations and declaring conflicts of interest were stated in 6 studies 
(Chantharangsikul et al., 2009; Chavalittumrong et al., 2009; Intayoong, 2006; Nusuetrong et 
al., 2012; Sirisangtragul and Sripanidkulchai, 2013; Sirisangtrakul and Sripanidkulchai, 2011) 
and 2 studies (Chantharangsikul et al., 2009; Nusuetrong et al., 2012), respectively.  Seven 
studies performed dose-response effects of Yahom (Chantharangsikul et al., 2009; 
Chavalittumrong et al., 2009; Jariyapongskul et al., 2006; Nusuetrong et al., 2012; 
Suvitayavat et al., 2004; Suvitayavat et al., 2005a; Suvitayavat et al., 2005b), but only 5 
studies used appropriate statistical tests (Chantharangsikul et al., 2009; Chavalittumrong et 
al., 2009; Nusuetrong et al., 2012; Suvitayavat et al., 2004; Suvitayavat et al., 2005b).  None 
of the studies used any pathological animal model, so the appropriate co-morbidity domain 
was not determined.  Quality of reporting was generally acceptable except for 
Matankasombat (Matangkasombat, 1974) where poor reporting made most of the data 
useless (Table 1).  Some studies were underpowered especially Kengkoom with only 2 rats 
for ischemia/reperfusion against which to compare drug action (Kengkoom et al., 2015).  In 
most studies validation of plant compositions of Yahom were not carried out (Table 5). 
However, four studies on tissue pathologies (Chavalittumrong et al., 2009; Kengkoom 
and Ampawong, 2015; Kengkoom et al., 2012; Thongpraditchote et al., 1999) had no 
mention of who made the histological assessments and lacked validation.  For the herbal 
domains, many studies stated Yahom herbal contents, some had HPLC profiles but did not 
compare powder and extract, and none provided all the information required by CONSORT 
and ARRIVE (Gagnier et al., 2006).   
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For the only human study (Suvitayavat et al., 2005), the risk of bias was unclear in 5 
domains including sequence generation, allocation concealment, blinding, outcome data 
addressed, and other sources of bias, while the risk of bias was low for selective outcome 
reporting but high for selective data analysis (compared with baseline rather than control 
group). 
CONSORT and ARRIVE also require reporting about the herbal treatments used.  
While several authors illustrated HPLC chromatograms of their extract, only 3 studies 
(Nalinratana et al., 2014; Sirisangtragul and Sripanidkulchai, 2013; Sirisangtrakul and 
Sripanidkulchai, 2011) compared different extraction methods and concluded that methylene 
chloride yielded most peaks with MeCl2 extraction, MeOH showed some similarities, while 
aqueous extraction showed markedly fewer peaks (Nalinratana et al., 2014).  Only one study 
identified peaks (Nalinratana et al., 2014).  Three other studies (Suvitayavat et al., 2004; 
Suvitayavat et al., 2005a; Suvitayavat et al., 2005b) provided HPLC chromatographs but the 
nature of individual peaks were not identified and the rationale for showing them unclear. 
3.5 Pharmacological effects of Yahom 
Intravenous Yahom transiently reduced MAP (~30 mmHg, ~30 s) followed by a 
longer pressor action, ~10 mmHg (Suvitayavat et al., 2005b) while a similar elevation 
followed single oral gavages (Jariyapongskul et al., 2006; Matangkasombat, 1974) (Table 1).  
A single oral dose increased regional cerebral blood flow in rats, which correlated with 
cerebral arteriolar vasodilatation (Jariyapongskul et al., 2006).  In rat isolated aorta, bath 
application of Yahom produced either a vasoconstriction (Suvitayavat et al., 2005a) or a 
vasodilatation (Nusuetrong et al., 2012), while in rat isolated atria Yahom increased force but 
reduced rate of contraction (Suvitayavat et al., 2005a). 
Yahom in anaesthetised rats (Suvitayavat et al., 2004) or mice (Chantharangsikul et 
al., 2009) (Table 2), either applied serosally or duodenally almost completely inhibited the 
gastric secretion elicited by histamine or muscarinic agonists.   
Cell-free studies rated Yahoms as moderately high phenolic content as judged by as 
high reducing capacities (Channarong et al., 2012; Nalinratana et al., 2014; Tuekaew et al., 
2014) (Table 3).  But how these translate to the in vivo environment is unclear.  
The human study on 15 healthy female volunteers showed that single oral doses (3 
g) of either Yahom powder in water or the same amount as lyophilized aqueous extract 
showed no convincing effects on blood pressure (MAP, systolic, or diastolic pressure) nor 
were ECG or cutaneous blood flow affected (Suvitayavat et al., 2005).  For the native 
powder only, MAP and diastolic pressure reportedly increased by ~2 mmHg at several time 
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points when compared to ‘0’ time.  When each time point is compared to the control 
corresponding control value, there were no differences (Table 4).    
In vitro, effective extract concentrations were highly variable: the most potent effects 
were aortic relaxation (0.001-0.1 mg/ml) (Nusuetrong et al., 2012), 1.7-17 mg/ml for aortic 
and atrial contraction (Suvitayavat et al., 2005b), and 2.5-20 mg/ml to inhibit gastric secretion 
(Chantharangsikul et al., 2009).  However, Nusuetrong et al., (Nusuetrong et al., 2012) used 
a prolonged EtOH extraction which might explain the different effect to that of Suvitayavat et 
al study (Suvitayavat et al., 2005b). 
Two studies used cell-free assays to measure phenolic/anti-oxidant potential and 
scavenging of specific oxidizing agents (Channarong et al., 2012; Nalinratana et al., 2014), 
but no evidence was cited that demonstrated these effects operated in vivo at the 
concentrations used, i.e., their biological contexts were unclear. 
In general, the non-human pharmacological studies used much higher Yahom 
concentrations or doses than those likely to be relevant to plasma of humans taking Yahom 
orally. 
3.6 Toxicity of Yahom 
There were 6 studies where rats (0.01-1 g/kg/day) or mice (2-16 g/kg/day) were fed 
with Yahom extracts using various solvents.  The most common maximum dose was 1 
g/kg/day of either native powder or extract which translated from rats to be equivalent in 
humans of 0.130 g/kg/day or ~10 g/day using an allometric conversion (Sharma and McNeill, 
2009).   For up to 4 g/kg/day (mice, acute) and up to 1 g/kg/day for 12 months (rats), there 
were no consistent changes in body weight, appetite, spontaneous behaviour, general 
macroscopic health, blood chemistry, haematology, and histology of liver (Chavalittumrong 
et al., 2009; Kengkoom and Ampawong, 2015).  For haematology, counts rose for leucocyte 
(males) and for platelets (females), both reversibly, in one study (Chavalittumrong et al., 
2009) but showed no changes in other studies (Kengkoom and Ampawong, 2015; 
Kengkoom et al., 2012).  The latter studies (Kengkoom and Ampawong, 2015; Kengkoom et 
al., 2012) also showed no changes blood chemistry, histology of liver, heart and lungs, nor 
other haematological parameters.  However, at the highest Yahom dosage rate, glomerular 
mesangiopathy was evident (but renal function appeared normal as judged by BUN and 
plasma creatinine) (Kengkoom et al., 2012).   
For LD50 determinations, 8 g/kg/day killed 1/10 mice while 7/10 died consuming 16 
g/kg/day suggesting an LD50 of around 11 g/kg/day of extract (Chavalittumrong et al., 2009). 
This scales to ~60 g/day in humans.  In two studies, mice fed two different Yahom 
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preparations for 4 weeks at low doses (1-5 mg/kg/day) showed reduced activities of hepatic 
drug metabolism enzymes including CYP1A1, CYP1A2 and CYP2E1 whereas CYP2B was 
increased by Yahom depending on the extraction solvent (Sirisangtragul and 
Sripanidkulchai, 2013; Sirisangtrakul and Sripanidkulchai, 2011).  Pentobarbital ‘sleeping’ 
times in rats were shortened by up to 75% also suggesting liver enzyme induction. 
Assessment of carcinogenicity and teratogenicity has relied on cell assays which 
showed no effect (Nernpermpisooth et al., 2015) but the concentrations tested were lower 
than some concentrations used to demonstrate cardiovascular effects.  One endothelial cell 
culture study found concentration-dependent toxicity > 200 g/ml extract (Nalinratana et al., 
2014). 
4. Discussion 
To the best of our knowledge, this is the first study to systematically summarise and 
review the scientific evidence derived from investigations on Yahom in both preclinical and 
human studies.  In preclinical studies, the cardiovascular effects were: (i) Vasorelaxation at 
the lowest concentrations (0.1 g/ml) of the Yahoms tested, explaining in one in vivo study, 
the transient hypotension, the increased cerebral blood flow and accordant pial dilatation. (ii) 
Aortic contractions and increased atrial rate and force of contraction explains the pressor 
effects of Yahom, i.e., increased MAP, SBP and HR, but at concentrations (1-17 mg/ml) 
higher than those showing endothelial toxicity (500 g/ml).  The main effect of Yahom (~20 
mg/ml or ~4 g/kg) on gastro-intestinal tract from preclinical studies was its inhibitory action 
on the hormonally stimulated gastric acid and other gastric secretions.  In most of these 
preclinical studies, it was suggested that the results support the traditional use of Yahom.  
But this is unlikely for anything needing in vitro concentrations > 1 mg/ml and in vivo doses > 
300 mg/kg are unlikely to be relevant to their medicinal actions.  More fundamentally, 
different Yahom formulations were used, or were undisclosed, especially in the 
cardiovascular studies. Thus, these actions may not be comparable with each other. 
However, the relevance of all these actions in rodents to those underlying some 
therapeutic effects of Yahom in humans remains unclear.  The use of Yahom may be of 
value in the treatment of syncope, because it increases blood pressure and cerebral blood-
flow, however syncope arises from many causes, and an anti-syncope action is difficult to 
test in rodents.  Yahom is a herbal remedy widely used among older Thais but ~50% of 
Thais aged over 50 yr are hypertensive, which contra-indicates any medicine raising BP per 
se.  Its inhibition of gastric secretion was suggested to support the traditional use of Yahom 
to treat abdominal discomfort, but gastro-intestinal discomfort is multifactorial and focusing 
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on gastric secretions is presumptive.  Thus, this pharmacological data sheds little light on the 
clinical actions of Yahom.   
The discovered studies suggest an acceptable safety profile, at least for Navagot, at 
the oral dosages recommended by the National Drug List (1-6 g/day).  Although Yahoms 
may share common therapeutic effects, their differing compositions does not necessarily 
mean that they have similar toxicity profiles. Furthermore, there is no human toxicity data.  
The low doses (1-5 mg/kg) that disrupted P450 enzymes is worrying because many of the 
consumers are elderly and likely to be prescribed other medications where potency changes 
could influence therapeutic or adverse outcomes (Sirisangtragul and Sripanidkulchai, 2013; 
Sirisangtrakul and Sripanidkulchai, 2011).  One adverse effect report was where an infant 
with high fever died of renal/liver failure.  In this case, the parents had over-dosed Five 
Pagodas, believing it would reverse her fever, although no causality was evident (WHO 
collaborating center for international drug monitoring, 1991).  Consumers of Yahom point to 
its use over hundreds of years and that this is sufficient claim safety.  But like all medicinal 
herbs, it should be integrated into pharmacovigilance programs.  Therefore, toxicity data in 
the discovered articles should be seen as supporting the ethnopharmacological safety 
information. 
No study reviewed carcinogenicity in vivo although potential renal toxicity was noted 
(Kengkoom and Ampawong, 2015).   However, one ingredient (Aristolochia pierei) is now 
banned in Thailand because aristolochic acid in Aristolochia species is nephrotoxic and 
causes urothelial malignancy in humans. This ingredient was only found in the Navagot 
formula.   It was classified as a human (class I) carcinogen (National Drug System 
Development Commission, 2011; World Health Organization International Agency for 
Research on Cancer, 2002). 
While non-human studies produced clear, unambiguous effects, they all tested 
different extracts rather than the native formulation sold as a medicine, and from different 
products, although some authors quoted doses as powder-equivalents.  The method of 
application also varied (oral, intraduodenal, intravenous, or bath addition for in vitro studies).  
Thus, the variation of effects recorded may reflect different spectra of constituents arising 
from product and extraction variations, as well as differences arising from limited 
bioavailability and metabolic degradation or activation.  Because the active ingredients are 
unknown, and no metabolism nor pharmacokinetic data available, selecting concentrations 
for relevant in vitro or intraparentral in vivo study is guesswork.  Above all, these studies 
cannot use the most appropriate animal models because the therapeutic actions and 
pathophysiological targets of Yahom are undefined.  Thus this lack design cohesion makes it 
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difficult to answer the key questions: in humans, does Yahom work, how does it work, can its 
efficacies be established, if so, can it be used safely? 
There are other limitations in our review that need to be highlighted. (i) The search 
terms were limited to Yahom/Ya-hom.  After thorough database searches and consultations 
with experts in herbal medicine, alternative terms for Yahom were not found.  However, 
additional papers (Kengkoom and Ampawong, 2015; Kengkoom et al., 2015; Nalinratana et 
al., 2014; Nusuetrong et al., 2012) were discovered that used the alternative term ‘a Yahom’.  
Three abstracts that never materialized into papers or other detailed scientific output were 
also found.  Similar products which might be sold elsewhere under different names were also 
not searched in this study.  (ii) Some experts suggested that reports might be hidden under 
confidentiality agreements.  (iii) There were some quality issues in the work covered in this 
study, where our analysis found numerous design, protocol defects, and lack of blinding 
which risks bias.  Nevertheless, these studies were mostly conducted to the standards 
prevailing at their inception. 
While most previous research focused on animal studies, human clinical trials using 
clearly defined symptomology to test the therapeutic value of Yahom are needed. The 
findings of this study suggest that a fundamental rethink is needed in clinical Yahom 
research by: (i) Quantifying real objectively assessable metrics and placebo effects.  (ii) 
Recruiting participants who use a Yahom preparation to treat a well-defined symptom using 
a rigorously designed placebo-controlled randomized clinical trial with amelioration of the 
symptom as the primary endpoint.  Dizziness in post-menopausal women might be a start, 
where the appropriate end-point might be postural hypotension.  (iii) Characterise this 
symptomatic relief in physiological terms using appropriate non-invasive testing methods 
(e.g., hypovolemia, hypoglycemia, autonomic dysfunction, vaso-vagal activation, sinus 
dysfunction, and well-being).  The latter cannot be ignored because of Thai traditional 
medicine’s holistic approach to treatment which may contribute to clinical outcomes.  (iv) 
Using HPLC to detect plasma compounds after consuming the medication and LC-MS to 
identify the likely chemical structures.  (v) Using animals is appropriate only when a good 
model for the disease is available and is treated with the native Yahom formulation as used 
by human patients.  (vi) Quality control of Yahom preparation is required and all species of 
plant material used need to be validated taxonomically, or traceable.  Above all, there needs 
good coordination between studies thus permitting data pooling.   
Although we focus here on experimental studies, the most valuable toxicity data 
comes from pharmacovigilance.  Therefore, adverse events of herbal medicines should be 
entered into the national reporting systems like any other medicine and the simplest way of 
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effecting this would be through mandatory product-labelled and verbal instruction, and made 
a pre-requisite of registration. 
Thus, the proposals which have emerged from this review might provide a model for 
redefining research into traditional medicines.  Finally, although this present work studied a 
product sold in one country, the discordances identified here have wider implications and are 
equally applicable to other traditional medicines. 
 
5. Conclusions 
This systematic review identifies limitations of studies into the pharmacological 
characterization of Yahom.  The included studies have some scientific rigor, yet are 
frustrated by their lack of fundamental therapeutic, pharmacological and pharmacokinetic 
clinical data relevant to Yahom as a herbal medicine to holistically treat specific symptoms.  
Instead, there needs a fundamental research re-alignment by: 
(i) Running, rigorously designed clinical trials where studies on participants experiencing 
relevant symptoms/pathologies 
(ii) Institute rigorous pharmacovigilance programs 
(iii) Underpin with later ‘preclinical’ and pharmacokinetic studies to improve product efficacy 
and safety. 
(iv) Identify the orally active ingredients in humans and weed out the non-essential 
components 
The model that emerged here provides a template for future rational research strategies in 
optimizing traditional medicines in general.  
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Appendix A. Supplementary materials  
Ingredients of commonly used Yahoms   
Most of Yahom formulae include some of the following plants i.e., Angelica dahurica Benth., 
Atractylodes lancea (Thung.) DC., Ligusticum chuanxiong Hort., Angelica sinensis (Oliv.) 
Diels, Artemisia annua L., Saussurea lappa C.B.Clarke, Picrorrhiza kurroa Royle. ex Benth., 
Terminalia chebula Retz., Nardostachys jatamansi (D. Don) DC., Nigella sativa L., Cuminum 
cyminum L., Lepidium sativum L., Foeniculum vulgare Mill. var. dulce Alef,  Trachyspermum 
ammi (L.) Sprague, Anethum graveolens L., Pimpinella anisum L., Plantago ovata Forssk, 
Carum carvi L..  In addition fragrant plants are also common to all Yahom preparations e.g. 
Aquilaria crassna Pierre ex Lecomte, Mesua ferrea  L., Mimusops elengi L., Cinnamomum 
loureirii Nees 
 
Five pagodas: 100 g contains  
Agastache rugosa (Fisch. et Mey) O. Kuntze (whole plant, Lamiaceae) 7.1 g, Acorus 
gramineus Sol. ex Aiton (rhizomes, Araceae) 3.5 g, Lysimachia foenum-graecum Hance 
(whole plant, Primulaceae) 3.3 g, Citrus nobilis Lour. (outer yellow rind of the ripe fruit, 
Rutaceae) 7.1 g, Magnolia officinalis Rehd. et Wils. (bark of stem, Magnoliaceae) 11.8g, 
Cinnamomum cassia Presl (Chinese cinnamon, bark, Lauraceae) 7.1 g, Mentha arvensis L. 
(Japanese mint, whole plant, Lamiaceae) 3.5 g, Asarum sieboldii Miq. (whole plant, 
Aristolochiaceae) 2.3 g, Ligusticum wallichii Franch. (rhizomes, Apiaceae) 9.3 g, Glycyrrhiza 
glabra L. (licorice, rhizomes, Fabaceae) 4.8 g, Eugenia caryophyllata Thunb. (clove, flower-
bud, Myrtaceae) 7.1 g, Saussuria lappa Clark (rhizomes, Asteraceae) 7.1 g, Aquilaria 
agallocha Roxb (wood, Thymelaeaceae) 7.1 g, Atractylis ovata Thunb. (rhizomes, 
Asteraceae) 9.3 g, menthol 4.7 g, Borneo camphor 1.4 g, Angelica anomala Lallem 
(rhizomes, Apiaceae) 3.5 g.  
Navagot (54 plants):   
Amomum testaceum Ridl., Aquailaria crassna Pierre ex Lecomte, Gymnopetalum chinense 
(Lour.) Merr., Euphorbia antiquorum L., Syzygium aromaticum (L.) Merr. et L.M. Perry, 
Saussurea lappa C.B.Clarke, Anacyclus pyrethrum (L.) Lagasca, Picrorhiza kurroa Royle ex 
Benth., Atractylodes lancea (Thung.) DC., Astemisia annua L., Angelica sinensis (Oliv.) 
Diels, Terminalia chebula Retz., Angelica dahurica Benth., Ligusticum sinense Oliv. cv. 
Chuanxiong, Mimusops elengi L., Zingiber officinale Roscoe, Aristolochia pierrei Lecomte, 
Dracaena loureiri Gagnep, Myristica fragrans Houtt, Santalum album L.,  Plumbago indica 
L., Alyxia reinwardtii Blume, Glycyrrhiza glabra L., Piper sarmentosum Roxb, Piper chaba 
Hunt, Plantago ovata Forssk, Cuminum cyminum L., Foeniculum vulgare Mill. var dulce Alef, 
Nigella sativa L., Lepidium sativum L., Anethum graveolens L., Trachyspermum ammi (L.) 
Sprague, Pimpinella anisum L., Tinospora crispa (L.) Miers ex Hook. f. & Thomson, 
Nelumbo nucifera Gaertn, Mesua ferrea L., Kaempferia galangal L., Coriandrum sativum L., 
Vetiveria zizanioides (L.) Nash ex Small, Mimusops elengi L., Phyllanthus emblica 
L.,Jasminum sambac (L.) Aiton, Brucea javanica (L.) Merr, Pinus sp.,Terminalia bellirica 
(Gaertn.) Roxb., Cinnamomum bejolghota (Buch.-Ham.) Sweet, Piper ribesoides Wall, 
Dalbergia parviflora Roxb, Sophora tomentosa L., Mammea siamensis Kosterm, Mollugo 
pentaphylla L., Cyperus rotundus L., Cinnamomum loureirii Nees.  
 
Phikud Navagot: main herbs from Navagot in equal amounts (each 11%):   
“Kot Soa” (root of Angelica dahurica (Fisch). Benth & Hook f., family Apiaceae),  
“Kot Khamao” (rhizome of Atractylodes lancea (Thunb.) DC., family Asteraceae), “Kot  
Hua Bua” (rhizome of Ligusticum chuanxiong Hort., family Apiaceae), “Kot Chiang” (root of 
Angelica sinensis (Oliv.) Diels, family Apiaceae), “Kot Chulalumpa” (aerial part of Artemisia 
vulgaris L., family Asteraceae), “Kot Kradook” (rhizome of Saussurea costus (Falc.) Lipsch., 
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family Asteraceae), “Kot Kan-Prao” (rhizome of Picrorhiza kurrooa Royle ex Benth., family 
Scrophulariaceae), “Kot Pung Pla” (gall of Terminalia chebula Retz., family Combretaceae) 
and “Kot Jatamansi” (root and rhizome of Nardostachys jatamansi (D. Don) DC., family 
Valerianaceae).  
 
Amanthong: Main ingredients as labelled:  
Conioselinum univilatum (selinum) (7.45%), Syzygium aromaticum (clove) (7.45%),  
Cinnamomum verum (cinnamon) (7.45%), Mesua ferrea (Bun-nak) (7.45%), Nelumbo 
nucifera (lotus) (7.45%), Glycyrrhiza glabra (licorice) (7.45%), Myristica fragrans (mace) 
(0.74%), Pogostemon cablin (phim-sen) (1.49%), Viverricula indica (0.09%)  
Intajak:   
Alyxia reinwardtii Blume, Amomum testaceum Ridl., Anacyclus pyrethrum (L.)  
Lagasca, Angelica dahurica Benth., Angelica sinensis (Oliv.) Diels, Aquilaria gallocha Roxb., 
Aristolochia pierrei Lecomte, Artemisia annua L., Atractylodes lancea (Thung.) DC., Bixa 
orellana L., Caesalpinia sappan L., Cananga odorata (Lam.) Hook. f & Thomson var. 
odorata, Cinnamomum bejolghota (Buch.-Ham.) Sweet, Cinnamomum verum J. Presl, 
Coriandrum sativum L., Cuminum cyminum L., Dracaena loureiri Gagnep., Enhalus 
acoroides (L.f.) Royle, Euphorbia antiquorum L., Foeniculum vulgare Mill. var dulce Alef, 
Gymnopetalum chinense (Lour.) Merr., Jasminum sambac (L.) Aiton, Lepidium sativum L., 
Mammea siamensis (Miq.) T. Anderson, Mesua ferrea L., Michelia champaca L., Mimusops 
elengi L.  
 
 
 
 
 
 
Table 1 Effects of Yahom on the Cardiovascular System 
References Animal & 
Study 
Model 
Yahom 
brand & 
Preparation* 
Concentration/Dose, 
Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologica
l data 
In vitro studies      
Pataloong & 
Sawasdimongkol
, 1995  
Male Wistar 
rats, n=8-
12/group 
In vitro study 
Four un-
named, 
brands, 
contents 
Yahom extract 
solution 0.25-1 mg/ml 
(5 min) alone or with 
acetylcholine (Ach) or 
Force and rate of 
atrial contraction 
to Yahom extract 
solution using 
Two brands at 
concentration 1 
mg/ml - slow 
onset with 
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References Animal & 
Study 
Model 
Yahom 
brand & 
Preparation* 
Concentration/Dose, 
Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologica
l data 
using 
isolated 
atria 
stated. 
Hot water 
extract 
solution 
isoproterenol organ bath 
technique 
 
positive 
ionotropic action 
and antagonised 
Ach effect 
One brand - no 
effect. 
Another brand - 
negative 
chronotropism 
Suvitayavat et 
al., 2005b  
Male Wistar 
rats, n=8-
10/group 
In vitro study 
using 
isolated 
aorta and 
atria 
Un-named 
brand, 
contents 
stated. 
Lyophilised 
water extract 
(then 
dissolved in 
water) 
 
Yahom extract 
solution 0.83, 1.67, 
8.33, 16.67 and 
83.33 mg/ml 
Contraction of 
isolated aortic ring 
to Yahom extract 
solution using 
organ bath 
technique 
Vasoconstriction 
of aortae via 
alpha receptors 
with maximal 
response at 
concentration 
1.7-17 mg/ml. 
 
 
 
   Force and rate of 
atrial contraction 
to Yahom extract 
solution using 
organ bath 
technique 
Increased force 
but reduced rate 
of atrial 
contraction at 
concentration > 
0.83 mg/ml 
Nusuetrong et 
al., 2012  
Male 
Sprague 
Dawley rats, 
n=5-6/group 
In vitro study 
using 
isolated 
aorta 
Phikud 
Navagot, 
Ethanolic 
extract (then 
dissolved in 
DMSO) 
Yahom solution 0.1-
300 g/ml, direct 
action or 
pretreatment (30 min) 
Vasorelaxation of 
isolated aortic ring 
to Yahom solution 
and its 
pretreatment (100 
g/ml, 30 min) on 
carbachol, sodium 
nitroprusside or 
methoxamine 
responses   using 
organ bath 
technique 
Vasorelaxation 
with pEC50  4 
g/ml, max 
response  70% 
(unaffected by 
pretreatment with 
N
G
-nitro L-
arginine methyl 
ester (LNAME) or 
indomethacin). 
Yahom pre-
treatment 
decreased 
endothelium-
dependent 
carbachol 
vasorelaxations 
In vivo studies      
Matankasombat, 
1974  
Rats and 
rabbits 
In vivo study 
Two un-
named 
brands 
Raw powder 
Oral 500 mg/kg/day 
(12-21 days) 
Blood pressure 
(BP) and heart 
rate (HR) 
measured via 
cannulation of 
femoral artery 
Positive 
chronotropic 
action in rats but 
not rabbits.  No 
effect on BP. 
No morphological 
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References Animal & 
Study 
Model 
Yahom 
brand & 
Preparation* 
Concentration/Dose, 
Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologica
l data 
Gross anatomy 
and size of liver, 
spleen, and heart 
were also 
determined 
changes 
(undefined). 
 
 
 
 Acute cardiac 
studies in vivo 
Isolated atria to 
measure force and 
rate of contraction 
induced by 
noradrenaline 
(NA), adrenaline, 
isoproterenol, Ach 
Doses and 
reporting 
confused, 
underpowered, 
no data analysis. 
Could not make 
conclusions. 
Suvitayavat et 
al., 2005a  
 
Male Wistar 
rats, n=8-
12/group 
In vivo study 
using 
normal 
anesthetise
d rats 
Five 
Pagodas, 
Lyophilised 
water extract 
(then 
dissolved in 
water) 
Intravenous injection 
(IV) 0.2-0.8 g/kg 
Mean arterial 
blood pressure 
(MAP) measured 
via cannulation of 
femoral artery 
Transient 
decreased in 
MAP (max effect 
at 0.4 g/kg, 
duration 18-36 s) 
followed by long 
lasting increased 
in MAP at dose > 
0.6 g/kg (duration 
1-30 min 
depending on 
dose) 
Jariyapongskul et 
al., 2006  
 
Male Wistar 
rats, n=5-
8/group 
In vivo study 
using 
normal 
anesthetise
d rats 
 
Un-named 
brand, extract 
and 
formulation 
not stated 
Prepared by 
dissolving it 
in 5% Tween 
solution for 
oral 
administratio
n and in 5% 
Tween plus 
artificial 
cerebrospinal 
fluid for 
superfusion 
on the pial 
cerebral 
cortex 
Single oral doses 2 or 
4 g/kg.bw 
MAP measured 
via cannulation of 
femoral artery and 
regional cerebral 
blood flow (rCBF) 
measured using 
laser Doppler flow 
meter after 0, 5, 
15, 30, 45, 60, 90, 
& 120 min.  
Increased MAP 
with max 
response at 45 
min (8% increase 
for 2 g/kg.bw and 
16% increase for 
4 g/kg.bw) and 
still 5% increase 
at 120 min 
Increased rCBF 
with max 
response at 15-
30 min (21% 
increase for 2 
g/kg.bw and 32% 
increase for 4 
g/kg.bw) then 
back to baseline 
at 120 min 
 
 
 
Dose 4 g/kg.bw was 
dissolved in 10 ml 5% 
Tween solution, and 
then diluted in ACSF 
(ACSF; compositions: 
NaCl 118.0, KCl 4.0, 
MgSO4 1.2, CaCl2 
Videometric 
cerebral arteriole 
diameter after NA 
preconstriction, 
topical Yahom 
application to pial 
surface 
Vasodilatation in 
pial microvessels 
(56% increase in 
arteriolar dilation 
compared to NA 
preconstriction) 
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References Animal & 
Study 
Model 
Yahom 
brand & 
Preparation* 
Concentration/Dose, 
Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologica
l data 
1.5, NaH2PO4 1.2, 
NaHCO3 25.0, 
glucose 5.0 in mM) 
with a concentration 
of 1:100 
(concentration 
unclear) 
Kengkoom et al, 
2015  
Male 
Sprague 
Dawley rats, 
n=2-5/group 
In vivo 
study, 
cardio-
protection 
after 
ischemia/ 
reperfusion 
(I/R) 
Phikud 
Navakot, 
Ethanolic 
extract, 
Dried + filler 
Yahom extract 0, 10, 
50,100, 200, 400 
mg/kg/day orally (7 
days)  
 
Yahom extract 
give orally 30 min 
left coronary 
occlusion, then 
released for 24 hr 
then measured:  
Infarct size (not 
quantified), 
plasma troponin1, 
lactate 
dehydrogenase, 
myocardial eNOS, 
HO1, ERK1/2, 
AKT, BAX/BCL2, 
blood biochemistry 
Controls too 
small (n=2 for IR 
alone) to make 
conclusions.  
Limited data 
suggest Yahom 
might promote 
myocardial 
damage.  Blood 
biochemistry 
stable except all 
animals (inc 
shams) very 
hyperglycaemic. 
Nernpermpisooth 
et al., 2015 
Male Wistar 
rats, 
n=10-
15/group 
In vivo 
chronic 
study  
Un-named 
brand, 
contents 
stated. 
Lyophilised 
water extract 
(then 
dissolved in 
water) 
Yahom extract 0, 1, 
2.5, 5.0 g/kg/day 
orally (8 weeks) 
 
Systolic blood 
pressure (SBP) 
and HR measured 
in conscious rats 
using tail-cuff 
plethysmography  
Acute increase of 
SBP and HR 
(~3%, at 15-45 
min) after the first 
dose of 2.5, 5 
g/kg/day 
At week 8, SBP 
increased (~3%) 
in all groups 
compared to 
baseline and no 
change in HR.  
No difference 
between control 
and treatment 
group. 
(Note, base-line 
BP high in all 
groups (138-143 
mmHg)). 
  Peripheral blood 
flow of hind paw 
skin measured in 
anesthetised rats 
using laser 
Doppler flowmetry 
Acute increase of 
blood flow (10% 
for 2.5 g/kg/d at 
30 min and 30% 
for 5 g/kg/d at 15-
90 min) 
 
 
 
Yahom extract 
solution 1-50 mg/ml 
in organ bath 
Contraction of 
aortic rings 
isolated from 
control and 5 
g/kg/day group: 
measured 
contractile 
NA sensitivity of 
aorta increased 
in Yahom chronic 
treatment group. 
Yahom (1-50 
mg/ml) induced 
aortic ring 
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References Animal & 
Study 
Model 
Yahom 
brand & 
Preparation* 
Concentration/Dose, 
Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologica
l data 
responses to 
Yahom and NA 
using organ bath 
technique 
contraction 
(higher in chronic 
Yahom treated 
group compared 
to control) 
Yahom (10 
mg/ml) reduced 
NA-induced 
contraction 
(10% in both 
groups).  
*See supplement material for available details of Yahom ingredients as it was stated in each reference 
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Table 2 Effects of Yahom on Gastrointestinal System  
References Animal & 
Study 
Model 
Yahom 
brand & 
Preparation
* 
Concentration/Dose, 
Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured 
and 
Technique 
used 
Basic 
pharmacological 
data 
In vitro study      
Chantharangsikul 
et al., 2009  
Male mice, 
n=6-
10/group 
In vitro study 
using 
isolated 
whole 
stomach 
Five 
Pagodas 
Lyophilised 
water extract 
Extract 2.5, 5, 10, 20 
mg/ml. 
(Concentration 
referred as powder) 
applied to serosal 
side (120 min) 
Extract 
solution 
applied to 
serosal side 
then measured 
gastric acid 
secretion 
induced by 
histamine or 
bethanechol 
Acid secretion 
dose dependently 
inhibited by 
Yahom (ID50 ~3 
mg/ml).  
Atropine 50% or 
ranitidine 100% 
lower secretion. 
In vivo studies      
Intayoong, 2006  Male Wistar 
rats, 
n=6/group 
In vivo study 
Ya-Hom 
powder, un-
named but 
contents 
listed. 
Boiling water 
extract.  
Yahom 1, 2, 4 g/kg 
(Dose referred as 
powder) 
Acute (4-6 hr) or 
Chronic (4 days) 
Acute effect: 
Oral 
administration 
of – water, 
vehicle, 
Yahom, or 
cimetidine 
(100 mg/kg). 
+30 min gastric 
ulcer induction 
by: HCl (0.6N), 
aspirin (200 
mg/kg), or 
stress 
induction by 
cold water-
immersion.  
Rats were 
terminated at 
4-6 hr, then 
measured 
lesion area 
and visible 
mucus 
secretion 
All Yahom doses 
and cimetidine 
reduced all 
lesions, strongly 
for 2, 4 g/kg 
Yahom, and 
cimetidine.  
Yahom (4 g/kg) 
attenuated mucus 
secretion. 
 Chronic effect: 
water-stress, 
then oral 
administration 
of 4 g/kg/day 
Yahom, 
cimetidine, or 
sucralfate for 4 
days 
Day 1 & 4, only 
Yahom protected 
in water-stress 
(gastric ulcers 
decreased by 
60%).  
Suvitayavat et Male Wistar 
rats, 
Five 
Pagodas, 
Intraduodenal 
injection of Yahom 
Intraduodenal 
injection of 
Yahom increased 
visible mucus 
Page 24  
 
al., 2004  
 
n=10/group  
In vivo study 
using 
normal 
anesthetise
d rats 
Lyophilised  
Water extract 
0.5-4 g/kg Yahom on 
secretion rates 
of gastric: 
blood flow, 
pepsin, acid, 
protein and 
soluble and 
visible mucus 
via gastric 
fistulae after 
histamine- or 
carbachol-
induction 
secretion, but 
decreased all 
other parameters 
dose-dependently 
*See supplement material for more detail of Yahom ingredients 
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Table 3 Toxicity and drug metabolism study of Yahom 
References Animal & 
Study 
Model 
Yahom brand 
& 
Preparation* 
Concentration/Dos
e, Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologic
al data 
In vitro studies      
Sripanidkulchai 
et al., 2007  
Salmonella 
typhimuriu
m TA98 
and TA100 
Navagot, 
Intarajuk, 
Prasarthong, 
Koklan and 
Sahasthara, 
Hexane pre-
extraction, 
95% ethanol 
and/or water 
extract 
Yahom extract 
solution 1-10 mg/ml 
(Dissolved in 
DMSO) (48 h 
incubation) 
Mutagenicity using 
Salmonella/microso
me mutagenicity 
Test (Ames test) 
and antimutagenicity 
Tested native 
extract, extract after 
rat liver enzyme or 
S-9 digestion. 
No mutagenic 
activity.  All 
extracts showed 
antimutagenisis 
at ~1 mg/ml 
against 
mutagens, 2-
aminoanthracen
e (2-AA), 2-
aminofluorene 
(AF2), and 4-
nitroguinolene-
1-oxide (4-
NQO). 
Tepsuwaan et 
al., 2011  
Salmonella 
typhimuriu
m Human 
hepatoma 
cell-line 
(HepG2) 
Fifty Thai 
traditional 
medicines - 11 
were Yahoms.  
MeOH 
extraction 
5-20 mg (Dissolved 
in DMSO) (48 h 
incubation) 
Mutagenicity using 
Salmonella/microso
me mutagenicity 
Test (Ames test) 
One Yahom 
sample showed 
mutagenic 
activity. 
 
 
0.2-1 g/ml 
(Dissolved in 
DMSO) (24 h 
incubation) 
Genotoxicity on 
HepG2 by Comet 
and binucleation 
Two Yahoms 
were genotoxic. 
Channarong et 
al., 2012  
Cell-free 
study 
Five un-named 
brands i.e., A, 
B, C, D, E 
Water extract 
1 g (Dried weight) Analysis of total 
phenolic compounds 
of Yahom powder 
and antioxidant 
capacity of Yahom 
using FRAP assays 
Fairly high 
amounts of total 
phenolic 
compounds and 
high FRAP 
values Brand E 
~3-fold higher 
contents than 
A-D 
Nalinratana et 
al., 2014 
Cell-free Phikud 
Navagot,  
50% EtOH or 
Water extracts 
200 mg/ml (Stock 
solution)  
Intracellular ROS 
scavenging & 
specific reactive 
species 
Herbal mixture 
more effective 
than sum of 
individual 
constituents  
Endothelial 
cell line 
200 mg/ml (Stock 
solution) 
Cytotoxicity 
Genotoxicity 
IC50 ~500 g/ml  
No gentoxicity 
up to 600 g/ml 
Tuekaew et al., 
2014  
Human 
blood Cell-
free 
Intajak and 47 
individual 
components,  
80% Ethanol 
extract: 
subfractions 
20-100 g/l (For 
DPPH assay) 
400-800 g/ml (For 
FRAP assay) 
Antioxidant effect 
study using 2,2-
diphenyl-1-
picrylhydrazyl 
(DPPH) radical 
scavenging capacity 
and ferric reducing 
Moderate DPPH 
scavenging 
activity: IC50 
~100 g/ml and 
a FRAP 
equivalent of 
1.12 mmol 
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References Animal & 
Study 
Model 
Yahom brand 
& 
Preparation* 
Concentration/Dos
e, Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologic
al data 
into n-hexane 
or 
dichlorometha
ne 
antioxidant power 
(FRAP) assays 
FeSO4/g.  Not 
clear how this 
translates into 
treatments. 
 
 
 
0.08-1.25 g/l Inhibition of human 
LDL peroxidation by 
thiobarbituric acid 
reactive substances 
(TBARS) assay 
Dichloromethan
e fraction had 
highest 
inhibitory effect 
on LDL 
peroxidation. 
Not clear how 
this relates to in 
vivo actions in 
humans 
In vivo studies      
Thongpraditcho
te et al., 1999  
Male & 
female 
Wistar rats 
and mice, 
n=6/group 
In vivo 
study 
5 Un-named 
brands, 
Compositions 
stated 
Dissolved in 
distilled water 
Oral single dose at 
5 g/kg or 
intraperitoneal 
injection (IP) single 
dose at 1, 2, 5 g/kg 
 
 
Oral doses 0.5, 1, 2 
g/kg/day for 5 
weeks 
Acute toxicity via 
oral or IP injection 
single dose, 
termination after 2 
weeks 
 
 
 
Subacute toxicity 
oral doses for 5 
weeks 
LD50 > 5 g/kg 
No change in 
body weight and 
%haematocrit 
compared to 
control 
Some Yahom 
formulas 
reduced visceral 
organ weight.  
No change in 
body weight, 
%haematocrit, 
SGOT, SGPT, 
BUN, and 
histology of 
visceral organs 
compared to 
control 
Chavalittumrong 
et al., 2009  
Male/ 
female 
mice, 
n=10/grou
p 
In vivo 
acute 
toxicity 
Navagot,  
Hexane and 
95% alcohol 
extract, then 
boiled in water 
30 min then 
filtered and 
dissolved with 
water before 
use 
Oral Yahom 2, 4, 8 
or 16 g/kg/day (14 
days) 
Acute toxicity of oral 
Yahom 
2 or 4 g/kg/day 
had no toxicity, 
8 or 16 g/kg/day 
produced 10% 
or 70% 
mortality. 
Male/femal
e Wistar 
rats, 
n=24/grou
p 
In vivo 
chronic 
toxicity 
Oral Yahom 10, 
100, 500, 1000 or 
1000 mg/kg/day (6 
months) 
Chronic toxicity of 
oral Yahom  
No effect on 
body weight, 
food 
consumption, 
behaviour, 
general health 
and clinical 
chemistry 
values.   
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References Animal & 
Study 
Model 
Yahom brand 
& 
Preparation* 
Concentration/Dos
e, Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologic
al data 
study 1000 mg/kg: 
increase in total 
leukocytes and 
platelet counts 
in male and 
female rats, 
respectively.  
Tended to 
recover 2 
weeks after 
Yahom 
discontinuation. 
Sirisangtrakul & 
Sripanidkulchai, 
2011 
Male mice, 
n=6-
16/group 
In vivo study 
using 
normal rats 
Ampanthong,  
CH2Cl2, MeOH 
or H2O 
extracts 
Oral each Yahom 
extract 1.2, 3, 5 
mg/kg/day (4 
weeks)  
Effect of oral Yahom 
extract on hepatic 
CYP1A1, CYP1A2, 
CYP3A4, CYP2B 
and CYP2E1 
All extracts 
inhibited 
CYP1A1, 
CYP1A2 and 
CYP2E1.  
CH2Cl2 & MeOH 
extracts 
enhanced 
CYP2B activity. 
IP Yahom extract 2 
g/kg 
Effect of IP Yahom 
i.e., CH2Cl2 extract 
on pentobarbital-
induced sleeping 
time  
Decreased 
pentobarbital-
induced 
sleeping time. 
Kengkoom et al, 
2012  
Male/femal
e rats, 
n=6/group 
In vivo 
chronic 
toxicity 
testing 
Phikud 
Navagot (9 
herbs) 
80% EtOH 
extract. Yield 
~22% of dried 
powder 
Oral Yahom extract 
0, 10, 100, 1000 
mg/kg/day (90 
days) 
Yahom extract for 90 
days, +/-14 day 
recovery. Monitored 
daily. Body weight 
Histology major 
organs, full blood 
chemistry, 
haematology 
Histology, blood 
chemistry - no 
changes with all 
doses of 
Yahom.  Small, 
sporadic 
reductions in 
food intake and 
weight 
reductions.  
Increased uric 
acid (also in ref 
39). Some 
hyperglycaemia 
but not in ref 39. 
Female 
rats, 
n=3/group 
Acute 
toxicity 
testing 
Oral Yahom extract 
2 g/kg (24 hr or 14 
days) 
2 g/kg 24hr acute, 
observed every 2 hr 
then daily for 14 
days 
Weight gain 
similar to 
chronic controls 
No changes up 
to 14 days 
Sirisangtragul & 
Sripanidkulchai, 
2013  
Male mice, 
n=3-
14/group 
In vivo 
study 
Tultavai,  
CH2Cl2, MeOH 
or H2O 
extracts 
Oral each Yahom 
extract 1.2, 3, 5 
mg/kg  
Effect on: hepatic 
CYP1A1, CYP1A2, 
CYP3A4, CYP2B 
and CYP2E1 
All extracts 
inhibited 
CYP1A1, 
CYP1A2 and 
CYP2E1.  
CH2Cl2 extract 
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References Animal & 
Study 
Model 
Yahom brand 
& 
Preparation* 
Concentration/Dos
e, Route of 
administration and 
Duration of 
treatment 
Protocols & 
Outcome 
parameter 
measured and 
Technique used 
Basic 
pharmacologic
al data 
using 
normal 
rats 
enhanced 
CYP2B activity. 
 
 
IP Yahom extract 2 
g/kg  
CH2Cl2 extract on 
pentobarbital 
sleeping time, 
compared with ethyl-
p-
methoxycinnamate 
Decreased 
pentobarbital-
induced 
sleeping time by 
75% 
Kengkoom & 
Ampawong, 
2015  
 
Sprague 
Dawley rats, 
n=10/group 
Animal 
specification 
not stated 
In vivo study 
Phikud Navagot 
(9 herbs) 
80% EtOH 
extract 
 
Yahom extract 10, 
100, 1000 
mg/kg/day (12 
months) 
Effect of Yahom 
extract on histology 
major organs, full 
blood chemistry, 
haematology and 
renal histochemistry.  
No differences 
between any of 
the groups for 
all measures, 
except  
marked bilateral 
mesangiolysis 
at 1000 
mg/kg/day with 
lowered 
aquaporin 1 
expression and 
increased heat 
shock protein. 
But renal 
excretion 
maintained.  
Estimated 
NOAEL=100 
mg/kg 
*See supplement material for more details of Yahom ingredients 
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Table 4 Effect of Yahom in Human 
References Study 
Desig
n 
Participants Yahom 
brand/ 
preparation 
Interventions Outcome 
Parameters 
Basic 
pharmacological data 
Suvitayavat 
et al., 2005  
3-arm 
cross-
over 
15 healthy 
females 
Age 20-23y 
BMI 18-23 
kg/m
2
 
Five 
Pagodas, 
powder, or 
Resuspende
d lyophilised 
water extract 
1.Water only 
2.Single dose 
of Yahom 
powder (3 g) 
suspended in 
50 ml 35
o
C 
water 
3.Single dose 
of lyophilized 
water extract  
Eq to 3g 
powder of 
Yahom 
powder  
 
Measured 
every 5 min 
for 60 min 
ECG Neither Yahom 
preparation affected 
ECG or heart rate 
 
 
 
 
 
 
BP Within-group 
(compared to time=0) 
Ya-hom Powder: 
Increased DBP by 
~2mmHg at 10, 20, 30, 
50 and 60 min 
compared to time 0 (p 
< 0.05) 
Increased MAP at 10, 
30 and 50 min from 0 
min (p < 0.05) 
Decreased pulse 
pressure at 60 min 
from 0 min (p < 0.05) 
Lyophilised water 
extract of Ya-hom: 
Increased MAP at 60 
min compared with 0 
min (p < 0.05) 
Yahom preparations 
compared with 
control 
No differences for any 
BP parameter 
 
 
Forearm 
cutaneous blood 
flow 
No change in forearm 
cutaneous blood flow  
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Adverse 
reactions 
No comments 
ECG = Electrocardiogram; BMI = body mass index; BP = blood pressure; DBP=diastolic blood pressure; MAP = 
mean arterial blood pressure  
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Table 5 Quality assessments of in vivo animal studies on Yahom action.  
Domain 
 
M
a
ta
n
k
a
s
o
m
b
a
t,
 1
9
7
4
 
T
h
o
n
g
p
ra
d
it
c
h
o
t 
e
t 
a
l.
, 
1
9
9
9
 
S
u
v
it
a
y
a
v
a
t 
e
t 
a
l.
, 
2
0
0
4
 
S
u
v
it
a
y
a
v
a
t 
e
t 
a
l.
, 
2
0
0
5
a
 
J
a
ri
y
a
p
o
n
g
s
k
u
l 
e
t 
a
l.
, 
2
0
0
6
 
In
ta
y
o
o
n
g
, 
2
0
0
6
 
C
h
a
v
a
lit
tu
m
ro
n
g
 e
t 
a
l.
, 
2
0
0
9
 
S
ir
is
a
n
g
tr
a
k
u
l 
 a
n
d
 
S
ri
p
a
n
id
k
u
lc
h
a
, 
2
0
1
1
, 
,2
0
1
3
 
K
e
n
g
k
o
o
m
 e
t 
a
l.
, 
2
0
1
2
 
N
e
rn
p
e
rm
p
is
o
o
th
 e
t 
a
l.
, 
2
0
1
5
 
K
e
n
g
k
o
o
m
 a
n
d
 
A
m
p
a
w
o
n
g
, 
2
0
1
5
 
K
e
n
g
k
o
o
m
 e
t 
a
l.
, 
2
0
1
5
 
Allocation sequence 
adequately 
generated? 
NR NR NR NR NR NR NR NR NR NR NR NR 
Was allocation 
adequately 
concealed? 
NR NR NR NR NR NR NR NR NR NR NR NR 
Blinding: allocated 
intervention 
concealed during 
study? 
NR NR NR NR NR NR NR NR NR NR NR NR 
Inclusion/exclusion 
criteria stated? 
No No No No No No No No No No No No 
Calculation or 
justification for 
sample size 
provided? 
No No No No No No No No No No No No 
Complied with 
animal 
ethics/welfare 
regulations? 
NR NR Yes NR NR Yes Yes Yes Yes Yes Yes Yes 
Conflict of interest 
statement & funding 
source given? 
Yes/No Yes No No No No No No Yes Yes Yes Yes 
Protocols/methods 
enough to repeat 
experiments 
No Yes Yes Yes Yes Yes/No Yes Yes Yes Yes Yes Yes 
Statistical tests 
appropriate for study 
design? 
No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Animals had 
appropriate 
comorbidity? (a) 
NA NA NA NA NA NA NA NA NA NA NA NA 
Test animal 
characteristics 
stated?  
No Yes Yes Yes Yes Yes NA Yes Yes Yes Yes Yes 
Statement about 
dose-response 
model? 
No No No No No No Yes No No No No No 
Details about why 
animals were 
removed from 
study? 
No No NA No No Yes No Yes Yes No No No 
Intervention duration 
enough to assess 
outcome? 
No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Product name, 
supplier, batch, etc. 
No No Yes/No Yes/No No No Yes Yes/No Yes No Yes/No Yes/No 
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Herbal composition 
adequately 
characterized & 
tested 
No Yes Yes Yes No Yes No Yes No Yes/No No No 
Taxonomic 
validation of 
medicinal plant 
composition 
No No No No No No Yes No No No No No 
Yahom source/brand 
stated 
No No Yes No Yes No No Yes Yes No No No 
Dosage range, 
method of 
administration 
Yes/ 
No 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Suitable 
placebo/negative 
control 
No No No No No No No No No No No No 
Positive control 
included 
Yes NA No Yes No Yes NA No NA No NA No 
NR = no report; NA = not applicable; These were marked as “NA” because Yahom actions in humans is unclear 
or study was toxicological. 
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